🔎 Trials Near Me

Home › Diffuse Large B-Cell Lymphoma › New York › Greenburgh

Diffuse Large B-Cell Lymphoma clinical trials in Greenburgh, NY

6 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Greenburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

RecruitingPhase 2
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale · 9 mi away
Ages 65 to 80 · All sexes · Updated Oct 30, 2026 · NCT06765317

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

RecruitingPhase 1/2
  • New York Medical College ( Site 1023), Valhalla · 5 mi away
6 Months – 25 Years · All sexes · Updated Oct 30, 2026 · NCT06395103

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

RecruitingPhase 1/2
  • New York Medical College, Valhalla · 5 mi away
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

RecruitingPhase 2
  • New York Medical College, Valhalla · 5 mi away
Ages 3 to 31 · All sexes · Updated Oct 23, 2026 · NCT02393157

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

RecruitingPhase 1/2
  • New York Medical Center, Valhalla · 5 mi away
Ages 12 to 70 · All sexes · Updated Apr 15, 2026 · NCT04491370

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

RecruitingPhase 2
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale · 9 mi away
Ages 18 and older · All sexes · Updated Dec 18, 2025 · NCT06736613

Diffuse Large B-Cell Lymphoma trials in other cities

Other studies in Greenburgh

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.